A Phase III, Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Pertuzumab+Herceptin+Docetaxel Versus Placebo+Herceptin+Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer
Latest Information Update: 13 Feb 2023
At a glance
- Drugs Docetaxel (Primary) ; Pertuzumab (Primary) ; Trastuzumab (Primary)
- Indications Adenocarcinoma; Advanced breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms PUFFIN
- Sponsors Roche
- 01 Feb 2023 Results of final analysis assessing consistency of efficacy and safety of pertuzumab plus trastuzumab and docetaxel compared with CLEOPATRA trial published in the Breast Cancer Research and Treatment
- 16 Feb 2021 Status changed from active, no longer recruiting to completed.
- 12 Aug 2020 Planned End Date changed from 24 Sep 2020 to 31 Mar 2021.